the aid library

Sort by:

Direction:

Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment

Lancaster, C.L., Teeters, J.B., Gros, D.F., Back, S.E. Journal of Clinical Medicine (2016) CC

Abstract: Posttraumatic stress disorder (PTSD) is a chronic psychological disorder that can develop after exposure to a traumatic event. This review summarizes the literature on the epidemiology, assessment, and treatment of PTSD. We provide a review of the characteristics of PTSD along with associa... more

Download (80)

View PDF (908)

Post Traumatic Stress Disorder in Children Sexsual Abuse

Eglantina Dervishi Academic Journal of Interdisciplinary Studies MCSER Publishing (2015) CC

The aim of this study is to research deeply on the post-traumatic stress disorder in sexually abused children. Proving the presence of forms of the disorder in children and the their treatment mode will be in the center of the study. The methods used to conduct this study will be a literature review... more

Download (111)

View PDF (168)

Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults

A. Locke, N. Kirst, C.G. Shultz American Academy of Family Physicians (2015) C2

Download (77)

View PDF (1127)

Treatment of anxiety disorders

B.Bandelo, S. Michaelis, D. Wedekind (2017) CC

Dialogues Clin Neurosci. 2017 Jun; 19(2): 93–107.

Download (171)

View PDF (216)

Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care

Ministry of Health and Consumer Affairs, Agencia Laín Entralgo. Unidad de Evaluación de Tecnologías Sanitaria, Madrid (2010) C2

The purpose of the Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care is to provide professionals with practical recommendations based on scientific evidence to assist in the detection and effective treatment of these disorders

Download (253)

View PDF (411)

Executive summary: the selection and use of essential medicines 2021

World Health Organization WHO (2021) C_WHO

Report of the 23rd WHO Expert Committee on the selection and use of essential medicines This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)... more

Download (97)

View PDF (141)

HIV/AIDS - Addressing the mental health needs of affected children and families

T. D. Benton; A. Lachman; S. Seedat IACAPAP (2013) C2

Psychatry & Pediatrics Chapter I.3

Download (90)

View PDF (167)

Pharmacological interventions for anxiety disorders in children and adolescents

World Health Organization WHO World Health Organization (2012) C_WHO

Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?

Download (563)

View PDF (703)

World Health Organization Model List of Essential Medicines 22st List
recommended

World Health Organization WHO (2021) C_WHO

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials... more

Download (146)

View PDF (249)

Depression in children and adolescents

J. M. Rey; T. T. Bella-Awusah; J. Liu IACAPAP (2015) C2

Mood disorders Chapter E.1 2015 edition

Download (133)

View PDF (167)

F2. Anxiete de Separation

Ana Figueroa, Cesar Soutullo, Yoshiro Ono & Kazuhiko Saito IACAPAP (2015) C1

Le trouble anxiété de séparation (TAS) représente environ la moitié de l’ensemble des troubles anxieux (Cartwright-Harton et al, 2006). La plupart des troubles anxieux pédiatriques présentent les mêmes critères diagnostics que chez l’adulte à l’exception du TAS, actuellement class... more

Download (140)

View PDF (147)

Sleep disorders in children and adolescents - A practical guide

S. Cortese; A. Ivanenko; U. Ramtekkar; et al. IACAPAP (2014) C2

Psychiatry and Pediatrics Chapter I.4

Download (118)

View PDF (178)

Principios de uso de medicación psicotrópica en niños y adolescentes

B. Vitiello IACAPAP (2016) C2

Introducción Capítulo A.7 Edición en español Editor: Juan José García-Orozco Traducción: Juan José García-Orozco y Carlos González Vivas Revisor de traducción: Laura Borredá Belda

Download (163)

View PDF (208)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (117)

View PDF (121)

Management of Gambling Disorders

Ministry of Health, Singapore (2011) CC

MOH clinical practice guidelines

Download (66)

View PDF (230)

COVID-19 Guidelines Module 5 - Drug therapy

National Department of Health, South Africa NDoH South Africa (2021) CC

Download (114)

View PDF (103)

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Download (62)

View PDF (121)

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended

Pan American Health Organisation PAHO (2022) C_WHO

This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up... more

Download (78)

View PDF (120)

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

World Health Organization Model List of Essential Medicines 22st List recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022 recommended

World Health Organization Model List of Essential Medicines 22st List
recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended